| Name | Title | Contact Details |
|---|
Hospria is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.
Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.
NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio`s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.